Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

PHASE3RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

July 14, 2022

Primary Completion Date

October 27, 2026

Study Completion Date

November 24, 2026

Conditions
Eosinophilic Granulomatosis With Polyangiitis
Interventions
BIOLOGICAL

Depemokimab

Depemokimab will be administered

BIOLOGICAL

Mepolizumab

Mepolizumab will be administered

DRUG

Placebo matching mepolizumab

Placebo matching to mepolizumab will be administered.

DRUG

Placebo matching depemokimab

Placebo matching to depemokimab will be administered.

Trial Locations (81)

1023

COMPLETED

GSK Investigational Site, Budapest

1070

RECRUITING

GSK Investigational Site, Brussels

3000

RECRUITING

GSK Investigational Site, Leuven

3080

RECRUITING

GSK Investigational Site, Seoul

8036

RECRUITING

GSK Investigational Site, Graz

10021

RECRUITING

GSK Investigational Site, New York

11030

RECRUITING

GSK Investigational Site, Manhasset

14059

WITHDRAWN

GSK Investigational Site, Prague

15261

RECRUITING

GSK Investigational Site, Pittsburgh

18014

RECRUITING

GSK Investigational Site, Granada

18016

RECRUITING

GSK Investigational Site, Granada

19104

RECRUITING

GSK Investigational Site, Philadelphia

20132

RECRUITING

GSK Investigational Site, Milan

20162

RECRUITING

GSK Investigational Site, Milan

23507

RECRUITING

GSK Investigational Site, Norfolk

25123

RECRUITING

GSK Investigational Site, Brescia

27100

RECRUITING

GSK Investigational Site, Pavia

28211

RECRUITING

GSK Investigational Site, Charlotte

29609

RECRUITING

GSK Investigational Site, Brest

31008

RECRUITING

GSK Investigational Site, Pamplona

31059

RECRUITING

GSK Investigational Site, Toulouse

31100

RECRUITING

GSK Investigational Site, Treviso

32610

RECRUITING

GSK Investigational Site, Gainesville

34295

RECRUITING

GSK Investigational Site, Montpellier

37208

WITHDRAWN

GSK Investigational Site, Nashville

44093

RECRUITING

GSK Investigational Site, Nantes

46026

RECRUITING

GSK Investigational Site, Valencia

50009

RECRUITING

GSK Investigational Site, Zaragoza

50134

RECRUITING

GSK Investigational Site, Florence

52621

RECRUITING

GSK Investigational Site, Ramat Gan

55905

RECRUITING

GSK Investigational Site, Rochester

56126

RECRUITING

GSK Investigational Site, Pisa

59037

RECRUITING

GSK Investigational Site, Lille

60126

RECRUITING

GSK Investigational Site, Torrette AN

61469

RECRUITING

GSK Investigational Site, Gwangju

70124

RECRUITING

GSK Investigational Site, Bari

74136

RECRUITING

GSK Investigational Site, Tulsa

75014

RECRUITING

GSK Investigational Site, Paris

79106

RECRUITING

GSK Investigational Site, Freiburg im Breisgau

80206

RECRUITING

GSK Investigational Site, Denver

85925

RECRUITING

GSK Investigational Site, La Roche-sur-Yon

92150

RECRUITING

GSK Investigational Site, Suresnes

100005

COMPLETED

GSK Investigational Site, Beijing

200032

COMPLETED

GSK Investigational Site, Shanghai

210006

COMPLETED

GSK Investigational Site, Nanjing

230001

COMPLETED

GSK Investigational Site, Hefei

266071

COMPLETED

GSK Investigational Site, Qingdao

325000

COMPLETED

GSK Investigational Site, Wenzhou

510000

WITHDRAWN

GSK Investigational Site, Guangzhou

510163

COMPLETED

GSK Investigational Site, Guangzhou

518020

COMPLETED

GSK Investigational Site, Shenzhen

4023900

RECRUITING

GSK Investigational Site, São Paulo

B1900

RECRUITING

GSK Investigational Site, La Plata

T4000

RECRUITING

GSK Investigational Site, San Miguel de Tucumán

M5T 3A9

RECRUITING

GSK Investigational Site, Toronto

M5T 3L9

RECRUITING

GSK Investigational Site, Toronto

180 81

WITHDRAWN

GSK Investigational Site, Prague

00128

RECRUITING

GSK Investigational Site, Roma

247-8533

RECRUITING

GSK Investigational Site, Kanagawa

252-0392

RECRUITING

GSK Investigational Site, Kanagawa

350-8550

RECRUITING

GSK Investigational Site, Saitama

162-8666

RECRUITING

GSK Investigational Site, Tokyo

181-8611

RECRUITING

GSK Investigational Site, Tokyo

9713 GZ

RECRUITING

GSK Investigational Site, Groningen

2333 ZA

RECRUITING

GSK Investigational Site, Leiden

80-952

RECRUITING

GSK Investigational Site, Gdansk

90-153

RECRUITING

GSK Investigational Site, Lodz

01-138

RECRUITING

GSK Investigational Site, Warsaw

1649-035

RECRUITING

GSK Investigational Site, Lisbon

4099-001

RECRUITING

GSK Investigational Site, Porto

561-712

RECRUITING

GSK Investigational Site, Jeonju

05505

RECRUITING

GSK Investigational Site, Seoul

06351

RECRUITING

GSK Investigational Site, Seoul

06591

RECRUITING

GSK Investigational Site, Seoul

08930

RECRUITING

GSK Investigational Site, Badalona

08035

RECRUITING

GSK Investigational Site, Barcelona

08036

RECRUITING

GSK Investigational Site, Barcelona

SE-205 02

RECRUITING

GSK Investigational Site, Malmo

B15 2GW

RECRUITING

GSK Investigational Site, Birmingham

CB2 2QQ

RECRUITING

GSK Investigational Site, Cambridge

SE1 7EH

RECRUITING

GSK Investigational Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT05263934 - Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Biotech Hunter | Biotech Hunter